Guerbet : NUCLIDIUM and Guerbet Form Strategic Partnership to Support the Advancement of targeted Copper-based Radiotheranostics.
May 22 2024 - 11:45AM
Guerbet : NUCLIDIUM and Guerbet Form Strategic Partnership to
Support the Advancement of targeted Copper-based Radiotheranostics.
NUCLIDIUM and Guerbet Form Strategic
Partnership to Support the Advancement of targeted Copper-based
Radiotheranostics
-- Agreement brings together Guerbet’s
industry leading expertise in medical imaging technologies,
production, and commercialization with Nuclidium’s in depth
know-how of the copper radioisotope production and theranostic
development --
Basel, Switzerland and Villepinte,
France, May 22, 2024 – NUCLIDIUM and Guerbet (GBT) today
announced a strategic partnership to advance NUCLIDIUM’s diagnostic
and therapeutic copper-based radiopharmaceuticals. This partnership
will provide NUCLIDIUM access to Guerbet’s knowledge and extensive
network in diagnostic imaging, manufacturing, and clinical trials,
aiding the progression of NUCLIDIUM’s theranostic candidates
towards commercialization. Guerbet has made a strategic,
non-exclusive investment in NUCLIDIUM as part of the agreement. As
part of the agreement, François Nicolas, Senior Vice President of
R&D at Guerbet, will join NUCLIDIUM’s Board of Directors as an
observer. No further details of the agreement have been
disclosed.
“Guerbet is a global leading expert in
diagnostic imaging with a longstanding record in developing,
manufacturing, and globally distributing medical imaging solutions.
This collaboration emphasizes the value of our innovative
copper-based theranostic pipeline, which aims to provide cancer
patients with comprehensive solutions from the precise diagnosis to
effective treatments. Our goal is to accelerate the clinical
development of our unique product candidates and we look forward to
gaining valuable strategic insights from François and the Guerbet
team,” said Leila Jaafar, PhD, CEO and Co-Founder of
NUCLIDIUM.
François Nicolas, Senior Vice President
of R&D Guerbet added: “NUCLIDIUM leads in pioneering a
new generation of targeted radiotheranostics that could vastly
extend patient benefits. Targeted radiopharmaceuticals represent a
significant advancement in cancer treatment, yet face supply
limitations and production challenges. NUCLIDIUM’s copper-based
strategy presents a promising approach to address these issues,
enhancing patient access and improving disease staging and
treatment. This aligns with Guerbet's growth strategy to broaden
our core business areas. I am excited to support Leila and her team
in demonstrating the clinical value of its platform.”
NUCLIDIUM is advancing a unique pipeline of
targeted copper-based radiopharmaceuticals leveraging isotopes 61Cu
and 67Cu. Its innovative platform facilitates a seamless transition
from diagnostic to therapeutic applications by merely exchanging
the isotopes on the same tumor-targeting molecule. The company will
apply its easy-to-produce manufacturing process to enhance product
availability and address major challenges in radiotheranostic
medicine to develop precise and effective theranostics for multiple
solid tumor types including prostate, colorectal, gastric, breast
and pancreatic cancers as well as neuroendocrine tumors. The
partnership with Guerbet is a critical pillar in NUCLIDIUM’s
strategy to establish valuable collaborations to advance its
proprietary pipeline and ensure reliable supply chains for its
copper-based radiopharmaceuticals.
About NUCLIDIUMNUCLIDIUM is
transforming precision oncology with its state-of-the-art
copper-based radiopharmaceuticals, delivering unmatched accuracy
and accessibility for targeted cancer treatment and diagnosis. Our
innovative CuTrace™ platform merges copper radiometals with
targeted cancer molecules, speeding up the creation of new
diagnostic and therapeutic solutions. This portfolio enhances
safety and efficacy, offering cost-effective solutions for
hospitals and patients. Our unique diagnostic-to-therapeutic model
simplifies development, tackling manufacturing and distribution
challenges to increase flexibility for medical providers. Our
diverse, interdisciplinary team is dedicated to revolutionizing
precision radio-oncology, significantly benefiting cancer
patients.
About GuerbetAt Guerbet, we
build lasting relationships so that we enable people to live
better. That is our purpose. We are a leader in medical imaging
worldwide, offering a comprehensive range of pharmaceutical
products, medical devices, and digital and AI solutions for
diagnostic and interventional imaging. A pioneer in contrast media
for 97 years, with more than 2,920 employees worldwide, we
continuously innovate and devote 10% of our sales to research and
development in four centers in France, the United States and
Israel. Guerbet (GBT) is listed on Euronext Paris (segment B – mid
caps) and generated €786 million in revenue in 2023.
For more information, please
contact:
NUCLIDIUMLeila Jaafar,
CEOEmail: info@nuclidium.com
GuerbetChristine Allard, Head
of CommunicationsEmail: christine.allard@guerbet.comPhone: +33 6 30
11 57 82
Investor/Media Contact
NUCLIDIUMTrophic CommunicationsStephanie May, PhDEmail:
may@trophic.euPhone: +49 171 1855682
- 20240521_Nuclidium_Guerbet Partnership PR_EN_final_clean
Guerbet (EU:GBT)
Historical Stock Chart
From Oct 2024 to Nov 2024
Guerbet (EU:GBT)
Historical Stock Chart
From Nov 2023 to Nov 2024
